why choose us

First received: September 19, 2022

Clinical Trial: Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy

Study Status: Completed

Recruit Status: RECRUITING

Condition: Metastatic Cancer

Study Type: INTERVENTIONAL


Official Title: Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy for Metastatic Urothelial Carcinoma With Stable or Responding Disease Following Platinum-based Chemothera

Brief Summary: A nonrandomized phase II trial is proposed combining avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin as switch maintenance therapy for mUC following stable or responding disease on 4-6 cycles of first line platinum-based chemotherapy

Read more